Navigation Links
Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Dose Escalation Trial with Tovaxin for Multiple Sclerosis

ion of CD8+ cytotoxic T-cells and CD4+CD25+FoxP3 Tregs specific for T-cell vaccine. The induction of anti-idiotypic cytotoxic CD8+ effector T-cells and anti-ergotypic CD4+CD25+FoxP3 positive Tregs is believed to provide a therapeutically effective dual mechanism of protection to patients treated with Tovaxin(TM). The observed regulatory immune responses have been shown to collectively correlate with clinical improvement in treated patients.

About Opexa Therapeutics

Opexa Therapeutics develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin(TM), a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for diabetes mellitus. For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements about Opexa Therapeutics' growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Opexa Therapeutics' ability to obtain additional funding, develop its stem cell technologies, achieve its operational objectives, and obtain patent protection
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
2. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
3. Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:5/27/2015)... Research and Markets( http://www.researchandmarkets.com/research/ljsxt8/asia_pacific ) has announced the ... Market - Growth, Trends And Forecasts (2014 - 2019)" ... Asia Pacific market for Portable X-Ray Devices is ... 2020 X-Ray is a form of electromagnetic radiation ... especially bones. The need of point of care diagnostics has ...
(Date:5/27/2015)... 2015 Doctors from the Sheikh Zayed ... National Health System are the first in ... osteoma, a benign but painful bone tumor that commonly ... magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) method. Two patients, ... Shah , have been treated successfully in a research ...
(Date:5/27/2015)... , May 25, 2015 Research ... of the "2015 Strategies in the Global ... This comprehensive seven-country report contains 650 ... current suppliers and potential market entrants identify and ... testing market during the next five years. ...
Breaking Medicine Technology:Asia Pacific Portable X Ray Devices Market 2015 - Trends And Forecasts to 2019 2Children's National first in US to destroy bone tumors with incisionless surgery 2Children's National first in US to destroy bone tumors with incisionless surgery 3Children's National first in US to destroy bone tumors with incisionless surgery 4Global Coagulation Testing Market Strategies 2015 2Global Coagulation Testing Market Strategies 2015 3
... Sept. 8 BHR Pharma, LLC ... 3, multi-center pivotal trial ( www.synapse-trial.com ) to evaluate ... a neuroprotective agent for treating severe traumatic brain injury (TBI) patients ... approximately 1,200 patients with severe (Glasgow Coma Scale scores of 4-8), ...
... , , University ... drive up high blood pressure, raise risk of heart attack , ... known that measures such as exercise, a healthy diet and not smoking ... Michigan Health System have determined the very air we breathe can be ...
Cached Medicine Technology:BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury 2Inhaling a Heart Attack: How Air Pollution Can Cause Heart Disease 2Inhaling a Heart Attack: How Air Pollution Can Cause Heart Disease 3
(Date:5/27/2015)... Calls Upon Individuals, Organizations and Communities to ... initiative – a “Summer of Service” – seeks the help ... to grow the number of individuals and organizations serving Veterans. ... Veterans by inviting the community to visit and explore opportunities ... from 1 – 3:00 p.m. in the auditorium. , “We ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 Ticket Down is a ... The Chicago Blackhawks are currently in the middle of their ... 3-2 in the series. If the Blackhawks can win tonight ... being played on Saturday, May 30th at the Honda Center in ... the best record in the Western Conference as they won the ...
(Date:5/27/2015)... Khanna Vision Institute (KVI) announced the launch ... on keratoconus eye disease . Keratoconus is commonly known ... onset in the teenage years. It worsens over the next ... clear part of the eye is defective. It becomes thin ... results in poor vision which cannot even be corrected with ...
(Date:5/27/2015)... York (PRWEB) May 27, 2015 ... filed on behalf of individuals who allegedly suffered ... to the use of the antipsychotic drug continue ... currently underway in Pennsylvania’s Philadelphia Court of Common ... proceeding with its bellwether trial program, as the ...
(Date:5/27/2015)... May 27, 2015 In today's healthcare ... tighter, it can be challenging for doctors and hospitals ... edge treatments. , Austin-based HealthTronics, Inc. ... invasive, mobile medical therapies for clinically sophisticated applications. The ... the acquisition of Laser Ventures, Inc ., a ...
Breaking Medicine News(10 mins):Health News:VA Begins “Summer of Service” to Bolster Volunteer Assistance for Veterans 2Health News:VA Begins “Summer of Service” to Bolster Volunteer Assistance for Veterans 3Health News:Blackhawks vs. Ducks NHL Western Conference Finals Tickets: Ticket Down Slashes Ticket Prices on Chicago Blackhawks vs. Anaheim Ducks 2015 NHL Western Conference Finals 2Health News:KVI announced the launch of The Keratoconus website focused on age based keratoconus treatment . 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 3Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 3
... announced today that the U.S. Food and Drug ... 360(TM) Orbital Atherectomy System (OAS),for removing plaque blockages ... device offers a promising new alternative for treating ... Disease,PAD. The clearance follows the successful completion ...
... BOSTON, Sept. 24 Small Army, the Boston-based ... for diabetes and,alleviating world poverty to their scope of ... "As communicators, we welcome the challenge to partner ... by a commitment,to truly make the world a better ...
... which advocates for physicians, joins forces with national, organization ... ... Americans, GREENSBORO, N.C., Sept. 24 Medical Justice,Services ... medical malpractice cases for the past five years, has,joined ...
... candidate from every Party to commit to creating a National ... ... Senator and,Presidential candidate John Edwards today released a policy paper calling,for ... for ensuring that every person living with HIV/AIDS,has access to quality ...
... who have had knee replacement surgery due to osteoarthritis ... on bmj.com today. , Osteoarthritis is the ... replacement surgery (knee arthroplasty) is a common procedure but ... out everyday tasks. , At present, it is ...
... Preparing Journalists to Cover the 2008 Health Care Proposals, WASHINGTON, Sept. ... Who: Journalists covering health care policy and the 2008 Presidential ... All-Expenses-Paid Four-Day Seminar for Journalists, A McCormick ... Available, When: November ...
Cached Medicine News:Health News:New Device for Clearing Blocked Arteries in the Legs Receives FDA Clearance for Peripheral Use - Procedures Performed Across the US Within First 48 Hours 2Health News:New Device for Clearing Blocked Arteries in the Legs Receives FDA Clearance for Peripheral Use - Procedures Performed Across the US Within First 48 Hours 3Health News:Small Army Takes on Cure for Diabetes and New Approach to Ending World Poverty with Addition of Non-Profit Accounts 2Health News:Medical Justice Services Inc. Joins Center for Health Transformation 2Health News:Medical Justice Services Inc. Joins Center for Health Transformation 3Health News:AIDS Action Council Commends Senator Edwards for Endorsing a National HIV/AIDS Strategy 2Health News:Health Care and the Presidential Campaign 2
Inquire...
... is ideal for repeated pipetting ... volume FInnpipettes offer the same ... Finnpipette Digital pipettes: New, ... Soft-touch tip ejection, Safety label, ...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
... The new Finnpipette Focus from ... to combine ergonomics with uncompromising ... handle plate offers a custom ... The new shorter tip cones ...
Medicine Products: